Table 1.
Characteristics of 2027 Treatment-Naive HIV-Infected Patients at Initiation of Combination Antiretroviral Therapy and Over the Course of 6579 Person-Years Follow-up, CFAR Network of Integrated Clinical Systems (CNICS), 2000–2008a
| Characteristic | Baseline | Follow-up |
| Participants/observations | 2027 patients | 21665 VL measures |
| Age, years | 39 (33–45) | 42 (35–48) |
| Sex | ||
| Male | 1646 (81%) | 17117 (79%) |
| Female | 381 (19%) | 4548 (21%) |
| Race/ethnicity | ||
| Caucasian/white | 1045 (52%) | 10580 (49%) |
| African American/black | 731 (36%) | 8482 (39%) |
| Other | 251 (12%) | 2603 (12%) |
| Men who have sex with men | 1085 (54%) | 11157 (52%) |
| Intravenous drug use | 303 (15%) | 3355 (15%) |
| ART initiation year | ||
| 2000–02 | 466 (23%) | 7673 (35%) |
| 2003–05 | 765 (38%) | 9453 (44%) |
| 2006–08 | 796 (39%) | 4539 (21%) |
| Initial ART regimen | ||
| NNRTI-based | 1414 (70%) | 15150 (70%) |
| PI/r-based | 613 (30%) | 6515 (30%) |
| Baseline CD4 cell count, cells/mm3 | 222 (97–325) | 197 (74–310) |
| Most recent CD4 cell count, cells/mm3 | N/A | 363 (208–541) |
| Baseline VL, log10 copies/mL | 4.8 (4.2–5.3) | 4.9 (4.2–5.4) |
| 24-week VL <2.6, log10 copies/mL | 1635 (81%) | 17091 (79%) |
| Most recent VL, log10 copies/mL | N/A | <2.6 (<2.6–<2.6) |
| Viremia copy-years, log10 copy × y/mL | N/A | 5.3 (4.9–6.3) |
| Follow-up, years | 2.7 (1.6–4.6) | N/A |
| VL measures contributed | N/A | 8 (4–15) |
Abbreviations: ART, combination antiretroviral therapy; HIV, human immunodeficiency virus; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor; VL, plasma HIV viral load.
a
Data are presented as N (%) or median (interquartile range) unless otherwise specified.